Metabolite detection is vital to document drug consumption in clinical and forensic configurations, and period I metabolites of isotonitazene and metonitazene are already recognized in genuine cases of use (Krotulski et al. 2020, 2021). Nonetheless, the focus was on reporting isotonitazene and metonitazene concentrations, and section II metabolites